©TheCanadian Journal ofUrology™: International Supplement, April 2014
References
1. SiegelR,Ma J,ZouZ, JemalA.Cancerstatistics,2014.
CACancer
J Clin
2014;64(1):9-29.
2. ZaorskyNG,TrabulsiEJ,Lin J,DenRB.Multimodality therapy
for patientswithhigh-riskprostate cancer: current status and
futuredirections.
SeminOncol
2013;40(3):308-321.
3. NiraulaS, LeLW, Tannock IF. Treatment of prostate cancerwith
intermittentversuscontinuousandrogendeprivation:asystematic
reviewof randomized trials.
JClinOncol
2013;31(16):2029-2036.
4. ScherHI,SawyersCL.Biologyofprogressive,castration-resistant
prostate cancer: directed therapies targeting the androgen-
receptor signalingaxis.
JClinOncol
2005;23(32):8253-8261.
5. KnudsenKE, Penning TM. Partners in crime: deregulation of
AR activity and androgen synthesis inprostate cancer. Trends
EndocrinolMetab
2010;21(5):315-3124.
6. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and
increased survival inmetastatic prostate cancer.
NEngl JMed
2011;364(21):1995-2005.
7. RyanCJ, SmithMR, deBono JSet al.Abiraterone inmetastatic
prostate cancerwithout previous chemotherapy.
NEngl JMed
2013;368(2):138-148.
8. Scher HI, Fizazi K, Saad F et al. Increased survival with
enzalutamide inprostate cancer after chemotherapy.
NEngl J
Med
2012;367(13):1187-1197.
9. de Bono JS, Oudard S, OzgurogluM et al. Prednisone plus
cabazitaxel ormitoxantrone formetastatic castration-resistant
prostate cancer progressing after docetaxel treatment: a
randomisedopen-label trial.
Lancet
2010;376(9747):1147-1154.
10.Tannock IF,deWitR,BerryWRetal.Docetaxelplusprednisone
ormitoxantroneplusprednisone foradvancedprostatecancer.
NEngl JMed
2004;351(15):1502-1512.
11.Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T
immunotherapy forcastration-resistantprostatecancer.
NEngl
JMed
2010;363(5):411-422.
12.Sturge J, Caley MP, Waxman J. Bone metastasis in prostate
cancer: emerging therapeutic strategies.
Nat Rev Clin Oncol
2011;8(6):357-368.
13.Fox JJ, SchoderH, Larson SM.Molecular imaging of prostate
cancer.
CurrOpinUrol
2012;22(4):320-327.
14.Cleeland CS, Gonin R, Hatfield AK et al. Pain and its
treatment in outpatientswithmetastatic cancer.
NEngl JMed
1994;330(9):592-596.
15.BubendorfL,SchopferA,WagnerUetal.Metastaticpatternsof
prostatecancer: anautopsystudyof1,589patients.
HumPathol
2000;31(5):578-583.
16.SabbatiniP,LarsonSM,KremerAetal.Prognosticsignificanceof
extentofdisease inbone inpatientswithandrogen-independent
prostate cancer.
JClinOncol
1999;17(3):948-957.
17.Turner SL, Gruenewald S, Spry N, Gebski V. Less pain does
equal better quality of life following strontium-89 therapy for
metastaticprostate cancer.
Br JCancer
2001;84(3):297-302.
18.PorterAT,McEwanAJ, Powe JEet al. Resultsof a randomized
phase-III trial toevaluate theefficacyof strontium-89adjuvant
to local field external beam irradiation in themanagement of
endocrineresistantmetastaticprostatecancer.
Int JRadiatOncol
Biol Phys
1993;25(5):805-813.
19.Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa
SD. Role of strontium-89 as adjuvant to palliative external
beam radiotherapy is questionable: results of a double-
blind randomized study.
Int JRadiatOncolBiolPhys
2003;56(5):
1397-1404.
20.Oosterhof GO, Roberts JT, de Reijke TM et al. Strontium(89)
chloride versus palliative local field radiotherapy in patients
withhormonalescapedprostatecancer:aphase IIIstudyof the
EuropeanOrganisation forResearchandTreatment ofCancer,
GenitourinaryGroup.
EurUrol
2003;44(5):519-526.
21.QuiltyPM,KirkD,Bolger JJetal.Acomparisonof thepalliative
effects of strontium-89 and external beam radiotherapy in
metastaticprostate cancer.
RadiotherOncol
1994;31(1):33-40.
22.SciutoR, FestaA, Rea S et al. Effects of low-dose cisplatin on
89Sr therapy forpainful bonemetastases fromprostatecancer:
a randomized clinical trial.
JNuclMed
2002;43(1):79-86.
23.Lewington VJ, McEwanAJ, Ackery DM et al. Aprospective,
randomised double-blind crossover study to examine the
efficacy of strontium-89 in pain palliation in patients with
advancedprostatecancermetastatic tobone.
Eur JCancer
1991;
27(8):954-958.
24.Serafini AN, Houston SJ, Resche I et al. Palliation of pain
associated with metastatic bone cancer using samarium-153
lexidronam: a double-blind placebo-controlled clinical trial.
JClinOncol
1998;16(4):1574-1581.
25.SartorO,ReidRH,HoskinPJetal. Samarium-153-Lexidronam
complex for treatment ofpainful bonemetastases inhormone-
refractoryprostate cancer.
Urology
2004;63(5):940-945.
26.Resche I, Chatal JF, PeckingAet al.Adose-controlled studyof
153Sm-ethylenediaminetetramethylenephosphonate (EDTMP)
in the treatment of patients with painful bone metastases.
Eur JCancer
1997;33(10):1583-1591.
27.Han SH, deKlerk JM, Tan S et al. The PLACORHEN study: a
double-blind, placebo-controlled, randomized radionuclide
study with (186)Re-etidronate in hormone-resistant prostate
cancer patients with painful bone metastases. Placebo
ControlledRheniumStudy.
JNuclMed
2002;43(9):1150-1156.
28.Maxon HR, 3
rd
, Schroder LE, Hertzberg VS et al. Rhenium-
186(Sn)HEDP for treatment of painful osseous metastases:
results of a double-blind crossover comparisonwith placebo.
JNuclMed
1991;32(10):1877-1881.
29.NilssonS, FranzenL, ParkerCet al. Two-year survival follow-
upof the randomized, double-blind, placebo-controlledphase
II study of radium-223 chloride in patients with castration-
resistant prostate cancer and bonemetastases.
ClinGenitourin
Cancer
2013;11(1):20-26.
30.Nilsson S, LarsenRH, Fossa SD et al. First clinical experience
with alpha-emitting radium-223 in the treatment of skeletal
metastases.
ClinCancerRes
2005;11(12):4451-4459.
31.Nilsson S, Strang P, Aksnes AK et al. A randomized, dose-
response, multicenter phase II study of radium-223 chloride
for the palliation of painful bone metastases in patients
withcastration-resistantprostatecancer.
Eur JCancer
2012;48(5):
678-686.
32.ParkerC,NilssonS,HeinrichDetal.Alphaemitterradium-223
and survival in metastatic prostate cancer.
N Engl J Med
2013;369(9):213-223.
33.ParkerCC, PascoeS,ChodackiAet al.Arandomized, double-
blind, dose-finding, multicenter, phase 2 study of radium
chloride (Ra 223) in patients with bone metastases and
castration-resistantprostatecancer.
EurUrol
2013;63(2):189-197.
34.Morgans AK, Smith MR. Bone-targeted agents: preventing
skeletal complications in prostate cancer.
Urol Clin North Am
2012;39(4):533-546.
35.Guise TA, Mundy GR. Cancer and bone.
Endocr Rev
1998;
19(1):18-54.
36.Vengalil S, O’Sullivan JM, Parker CC. Use of radionuclides in
metastatic prostate cancer: pain relief and beyond.
Curr Opin
Support PalliatCare
2012;6(3):310-315.
37.Robinson RG. Strontium-89--precursor targeted therapy
for pain relief of blasticmetastatic disease.
Cancer
1993;72(11):
3433-3435.
38.Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89
therapy: strontium kinetics in disseminated carcinoma of the
prostate.
Eur JNuclMed
1986;12(9):447-454.
39.Finlay IG, Mason MD, Shelley M. Radioisotopes for the
palliationofmetastaticbonecancer:asystematicreview.
Lancet
Oncol
2005;6(6):392-400.
75
DenETAL.
